文献速递结核与非结核分枝杆菌

南非启动含贝达喹啉或含注射剂短程利福平耐药结核治疗方案后24个月的治疗结局:一项回顾性队列研究

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
PubMed 文献 · Lancet Infect Dis · 2022-05-02

该研究比较南非利福平耐药结核患者使用含贝达喹啉全口服短程方案或含注射剂短程方案后24个月结局。贝达喹啉组治疗成功率较注射剂组高14%(95%CI 8-20),失访低4%(95%CI 1-8),无病生存高2%(95%CI 0-5)。作者认为该发现支持在符合条件的患者中使用含贝达喹啉短程方案。

要点

  • 贝达喹啉组24个月治疗成功率70%,注射剂组57%,调整后风险差14%(95%CI 8-20)。
  • 贝达喹啉组失访率6%,注射剂组12%,调整后风险差-4%(95%CI -8至-1)。
  • 贝达喹啉组治疗期间死亡风险较注射剂组低8%(95%CI 4-11),治疗结束后无差异。

核心结论

  • 贝达喹啉组在24个月时治疗成功率显著高于注射剂组,作者认为该发现支持在符合条件的患者中使用含贝达喹啉短程方案。

研究设计与样本

  • 回顾性队列研究,纳入2017年1月1日至12月31日在南非开始短程治疗的≥18岁利福平耐药结核患者,共1387例(贝达喹啉组688例,注射剂组699例)。
  • 贝达喹啉剂量为400 mg每日一次用两周,随后200 mg每周三次用22周。
  • 采用精确匹配(HIV和ART状态、既往结核治疗史、基线抗酸杆菌涂片和培养结果)和倾向评分匹配(年龄、性别、治疗省份、异烟肼耐药状态)比较方案。
  • 采用二项线性回归估计24个月结局的调整风险差(aRD)及95%CI。

主要发现

  • 贝达喹啉组治疗失败或复发4例(1%),注射剂组17例(2%)。
  • 贝达喹啉组失访44例(6%),注射剂组87例(12%)。
  • 贝达喹啉组死亡162例(24%),注射剂组199例(28%)。
  • 调整后治疗成功率贝达喹啉组70% vs 注射剂组57%,aRD 14%(95%CI 8-20)。
  • 调整后失访率贝达喹啉组6% vs 注射剂组12%,aRD -4%(95%CI -8至-1);无病生存率99% vs 97%,aRD 2%(95%CI 0-5)。

关键数值与推荐

  • 治疗成功定义为治愈或完成治疗且无复发证据,贝达喹啉组70% vs 注射剂组57%,aRD 14%(95%CI 8-20)。
  • 治疗期间死亡风险贝达喹啉组17.0% vs 注射剂组22.4%,aRD -8%(95%CI -11至-4)。
  • 治疗结束后死亡风险两组无差异。

临床怎么用

  • 作者认为该发现支持在符合条件的患者中使用含贝达喹啉短程方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a need for short and safe all-oral treatment of rifampicin-resistant tuberculosis. We compared outcomes up to 24 months after treatment initiation for patients with rifampicin-resistant tuberculosis in South Africa treated with a short, all-oral bedaquiline-containing regimen (bedaquiline group), or a short, injectable-containing regimen (injectable group). METHODS: Patients with rifampicin-resistant tuberculosis, aged 18 years or older, eligible for a short regimen starting treatment between Jan 1 and Dec 31, 2017, with a bedaquiline-containing or WHO recommended injectable-containing treatment regimen of 9-12 months, registered in the drug-resistant tuberculosis database (EDRWeb), and with known age, sex, HIV status, and national identification number were eligible for study inclusion; patients receiving linezolid, carbapenems, terizidone or cycloserine, delamanid, or para-aminosalicylic acid were excluded. Bedaquiline was given at a dose of 400 mg once daily for two weeks followed by 200 mg three times a week for 22 weeks. To compare regimens, patients were exactly matched on HIV and ART status, previous tuberculosis treatment history, and baseline acid-fast bacilli smear and culture result, while propensity score matched on age, sex, province of treatment, and isoniazid-susceptibility status. We did binomial linear regression to estimate adjusted risk differences (aRD) and 95% CIs for 24-month outcomes, which included: treatment success (ie, cure or treatment completion without evidence of recurrence) versus all other outcomes, survival versus death, disease free survival versus survival with treatment failure or recurrence, and loss to follow-up versus all other outcomes. FINDINGS: Overall, 1387 (14%) of 10152 patients with rifampicin-resistant tuberculosis treated during 2017 met inclusion criteria; 688 in the bedaquiline group and 699 in the injectable group. Four patients (1%) had treatment failure or recurrence, 44 (6%) were lost to follow-up, and 162 (24%) died in the bedaquiline group, compared with 17 (2%), 87 (12%), and 199 (28%), respectively, in the injectable group. In adjusted analyses, treatment success was 14% (95% CI 8-20) higher in the bedaquiline group than in the injectable group (70% vs 57%); loss to follow-up was 4% (1-8) lower in the bedaquiline group (6% vs 12%); and disease-free survival was 2% (0-5) higher in the bedaquiline group (99% vs 97%). The bedaquiline group had 8% (4-11) lower risk of mortality during treatment (17·0% vs 22·4%), but there was no difference in mortality post-treatment. INTERPRETATION: Patients in the bedaquiline group experienced significantly higher rates of treatment success at 24 months. This finding supports the use of short bedaquiline-containing regimens in eligible patients. FUNDING: WHO Global TB Programme. TRANSLATION: For the French translation of the abstract see Supplementary Materials section.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Ndjeka N, Campbell JR, Meintjes G, et al. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study. Lancet Infect Dis. 2022. PMID: 35512718. doi:10.1016/S1473-3099(21)00811-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。